MX336154B - Tratamiento de atrofia vaginal en mujeres con riesgo de patologia tumoral. - Google Patents

Tratamiento de atrofia vaginal en mujeres con riesgo de patologia tumoral.

Info

Publication number
MX336154B
MX336154B MX2011001382A MX2011001382A MX336154B MX 336154 B MX336154 B MX 336154B MX 2011001382 A MX2011001382 A MX 2011001382A MX 2011001382 A MX2011001382 A MX 2011001382A MX 336154 B MX336154 B MX 336154B
Authority
MX
Mexico
Prior art keywords
women
treatment
vaginal atrophy
tumor pathology
pathology risk
Prior art date
Application number
MX2011001382A
Other languages
English (en)
Other versions
MX2011001382A (es
Inventor
Dolores Blanco Lousame
Jaime Moscoso Del Prado
Alvaro Acebrón Fernández
Concepción Nieto Magro
Original Assignee
Itf Res Pharma Slu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41012001&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX336154(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Itf Res Pharma Slu filed Critical Itf Res Pharma Slu
Publication of MX2011001382A publication Critical patent/MX2011001382A/es
Publication of MX336154B publication Critical patent/MX336154B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere al uso de estriol en la preparación de una formulación farmacéutica de administración vaginal con la capacidad de autolimitar la absorción de estriol, para la prevención y/o el tratamiento de atrofia urogenital en mujeres, teniendo dichas mujeres una alta probabilidad de desarrollar un tumor estrógeno-dependiendo o que padecen o han padecido un tumor estrógeno-dependiente.
MX2011001382A 2008-08-07 2009-08-07 Tratamiento de atrofia vaginal en mujeres con riesgo de patologia tumoral. MX336154B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200802384A ES2344673B1 (es) 2008-08-07 2008-08-07 Uso de estriol en la preparacion de una formulacion farmaceutica parael tratamiento de atrofia vaginal en mujeres con riesgo de potologiatumoral.
PCT/EP2009/060307 WO2010015718A1 (en) 2008-08-07 2009-08-07 Treatment of vaginal atrophy in women with tumor pathology risk

Publications (2)

Publication Number Publication Date
MX2011001382A MX2011001382A (es) 2011-03-29
MX336154B true MX336154B (es) 2016-01-11

Family

ID=41012001

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011001382A MX336154B (es) 2008-08-07 2009-08-07 Tratamiento de atrofia vaginal en mujeres con riesgo de patologia tumoral.

Country Status (23)

Country Link
US (1) US9114143B2 (es)
EP (1) EP2328589B1 (es)
JP (1) JP6207118B2 (es)
KR (1) KR101790652B1 (es)
CN (1) CN102170886A (es)
BR (1) BRPI0917265A2 (es)
CA (1) CA2732877C (es)
CL (1) CL2011000252A1 (es)
CO (1) CO6351732A2 (es)
CY (1) CY1120962T1 (es)
DK (1) DK2328589T3 (es)
ES (2) ES2344673B1 (es)
HR (1) HRP20182020T1 (es)
HU (1) HUE041377T2 (es)
LT (1) LT2328589T (es)
MX (1) MX336154B (es)
PE (1) PE20110682A1 (es)
PL (1) PL2328589T3 (es)
PT (1) PT2328589T (es)
RU (1) RU2504381C2 (es)
SI (1) SI2328589T1 (es)
SM (1) SMT201800647T1 (es)
WO (1) WO2010015718A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3098602A1 (en) * 2018-05-02 2019-11-07 Pantarhei Oncology B.V. Treatment of advanced estrogen receptor positive breast cancer
CN110151680A (zh) * 2019-04-10 2019-08-23 重庆医药高等专科学校 雌三醇凝胶产品及制备方法
CN114588252A (zh) * 2022-04-08 2022-06-07 暨南大学附属第一医院（广州华侨医院） 一种用于缓解阴道萎缩和干燥症的组合物及其应用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1866M (fr) 1961-04-07 1963-06-17 Vismara Francesco Spa Nouveaux éthers des hormones oestrogenes.
US4436738A (en) * 1982-03-15 1984-03-13 Mead Johnson & Company Stabilized estradiol cream composition
DE3486448T2 (de) 1983-11-14 1997-10-09 Columbia Lab Inc Bioadhäsive Mittel
US5719197A (en) 1988-03-04 1998-02-17 Noven Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
WO1991006289A1 (en) 1989-10-31 1991-05-16 Watson Laboratories, Inc. Mucoadhesive carrier for delivery of therapeutical agent
EP0431719B1 (en) 1989-10-31 1994-11-09 Columbia Laboratories, Inc. Vaginal tissue moisturizing composition
US5340586A (en) 1991-04-12 1994-08-23 University Of Southern California Methods and formulations for use in treating oophorectomized women
US5543150A (en) 1993-09-15 1996-08-06 Columbia Laboratories, Inc. Method of progesterone delivery and affect thereof
IL110024A (en) * 1994-06-15 1998-04-05 Yissum Res Dev Co Controlled release oral drug delivery system containing hydrogel- forming polymer
US5667492A (en) 1994-10-07 1997-09-16 Columbia Laboratories, Inc. Use and composition of an anti-sexually transmitted diseases formulation
AT408067B (de) 1995-03-17 2001-08-27 Gebro Pharma Gmbh Pharmazeutische zusammensetzung zur topischen applizierung und verfahren zu ihrer herstellung
US5741525A (en) 1995-10-24 1998-04-21 Marshall University Research Corporation Vaginal pharmaceutical hydrogen peroxide composition
IT1275816B1 (it) 1995-10-27 1997-10-17 Montefarmaco Spa Composizioni farmaceutiche solide per uso vaginale
AU714797B2 (en) 1996-06-14 2000-01-13 Mcneil-Ppc, Inc. Moisture containing compositions that are spreadable onto and adherable to biomembranes, methods of making and use thereof
IT1284874B1 (it) 1996-08-02 1998-05-22 Farmigea Spa Complessi bioadesivi di polycarbophil e farmaci antifungini o antiprotozoari azolici
US5942243A (en) 1996-11-12 1999-08-24 Polytherapeutics, Inc. Mucoadhesive compositions for administration of biologically active agents to animal tissue
ATE442844T1 (de) 1996-11-14 2009-10-15 Lipomedica Ehf Topische zusammensetzungen enthaltend als therapeutisch aktiven wirkstoff ein monoglycerid zur behandlung von schleimhautinfektionen
DE69819748T2 (de) 1997-09-12 2004-09-30 Columbia Laboratories (Bermuda) Ltd. Arzneimittel zur behandlung von dysmenorrhöe und verfrühten wehen
US6159491A (en) 1999-02-12 2000-12-12 Biovector Technologies, Inc. Prolonged release bioadhesive vaginal gel dosage form
ATE481108T1 (de) 1999-02-26 2010-10-15 Novartis Vaccines & Diagnostic Verwendung von bioadhaesiven und adjuvantien für die mukosale anwendung von antigenen
UA74168C2 (uk) 1999-10-05 2005-11-15 Коламбіа Леборетеріс (Бермуда) Лімітед Лікування ендометріозу або безпліддя, або покращення плідності та застосування бета-адренергічного агоніста для виробництва лікарського засобу
JP2003512310A (ja) 1999-10-22 2003-04-02 リーフ−フラウプ イーエイチエフ バイオ−ゲルズ ファーマシューティカルス インコーポレイテッド 粘膜上皮潰瘍および／または糜爛の治療用製薬組成物
CA2418135C (en) 2000-08-03 2011-09-20 Antares Pharma Ipl Ag Novel composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels
US20040092494A9 (en) 2000-08-30 2004-05-13 Dudley Robert E. Method of increasing testosterone and related steroid concentrations in women
US7709026B2 (en) 2001-10-29 2010-05-04 Columbia Laboratories, Inc. Low concentration of peroxide for treating or preventing vaginal infections
TWI336627B (en) * 2003-05-23 2011-02-01 Organon Nv Drug delivery system,and use and manufacturing method thereof
ES2237298B1 (es) * 2003-07-16 2006-11-01 Italfarmaco, S.A. Formulaciones mucoadhesivas semisolidas.
CN101351188A (zh) 2005-08-12 2009-01-21 药物技术公司 雌激素组合物和应用它们的治疗方法
JP2009519926A (ja) * 2005-12-16 2009-05-21 ライル コーポレート ディベロップメント インコーポレーテッド エストロゲンの非全身性膣投与による膣組織の再生
WO2007076144A2 (en) * 2005-12-27 2007-07-05 Duramed Pharmaceuticals, Inc. Conjugated estrogen compositions, applicators, kits, and methods of making and use thereof
CA2637608A1 (en) * 2006-01-20 2007-07-26 Pear Tree Pharmaceuticals, Inc. Method of treating atrophic vaginitis
EP1872775A1 (en) 2006-06-29 2008-01-02 Polichem S.A. Use of a hydrophilic matrix comprising a polyacrylic acid derivative, a cellulose ether and a disintegrant for the manufacture of a medicament for treating female genital disorders
WO2008089405A1 (en) 2007-01-19 2008-07-24 Neurosci, Inc. Composition of multiple hormones delivered vaginally in a single cream
ES2310968B1 (es) * 2007-06-25 2010-02-08 Italfarmaco, S.A. Uso de estriol en bajas dosis.

Also Published As

Publication number Publication date
US9114143B2 (en) 2015-08-25
WO2010015718A1 (en) 2010-02-11
LT2328589T (lt) 2019-01-10
SMT201800647T1 (it) 2019-01-11
EP2328589B1 (en) 2018-09-19
KR20110045041A (ko) 2011-05-03
US20110183950A1 (en) 2011-07-28
BRPI0917265A2 (pt) 2015-11-10
CA2732877A1 (en) 2010-02-11
SI2328589T1 (sl) 2019-02-28
PT2328589T (pt) 2018-12-18
RU2011108548A (ru) 2012-09-20
EP2328589A1 (en) 2011-06-08
JP2011529951A (ja) 2011-12-15
PL2328589T3 (pl) 2019-05-31
RU2504381C2 (ru) 2014-01-20
MX2011001382A (es) 2011-03-29
ES2344673A1 (es) 2010-09-02
JP6207118B2 (ja) 2017-10-04
PE20110682A1 (es) 2011-09-28
HRP20182020T1 (hr) 2019-01-25
CL2011000252A1 (es) 2011-11-18
CO6351732A2 (es) 2011-12-20
ES2700614T3 (es) 2019-02-18
CN102170886A (zh) 2011-08-31
HUE041377T2 (hu) 2019-05-28
KR101790652B1 (ko) 2017-11-20
CY1120962T1 (el) 2019-12-11
DK2328589T3 (en) 2018-12-10
ES2344673B1 (es) 2011-05-03
CA2732877C (en) 2017-04-18

Similar Documents

Publication Publication Date Title
MX2009013427A (es) Uso de estirol en bajas dosis.
MX2012003823A (es) Composiciones de corticosteroides administradas oralmente.
NZ602219A (en) Methods and compositions for treating degos’ disease
TN2015000174A1 (en) Pyrrolopyrimidine compounds as kinase inhibitors
AU2013299841A8 (en) Pharmaceutical combinations comprising a B-Raf inhibitor, an EGFR inhibitor and optionally a PI3K-alpha inhibitor
NZ602953A (en) Phytocannabinoids in the treatment of cancer
MX2011010390A (es) Conjugados, particulas, composiciones de agentes polimericos y metodos relacionados de uso.
EA201170940A1 (ru) Лечение рака с использованием комбинации бендамустина и анти-cd20-антитела
MA39094B1 (fr) Polythérapie comprenant un inhibiteur de mdm2 et un ou plusieurs principes pharmaceutiquement actifs supplémentaires pour le traitement de cancers
SG166093A1 (en) Inhibitors of brutonæs tyrosine kinase
WO2007127273A3 (en) Methods and compositions for altering cell function
BR112014031914A2 (pt) cápsula de estradiol solúvel para inserção vaginal
IN2012DN03172A (es)
CU20130134A7 (es) Uso de 2,3- dihidroimidazo [1,2 - c] quinazolinas sustituidas
CL2007001724A1 (es) Uso de un estrogeno para el tratamiento de enfermedades, condiciones o sintomas asociados con niveles deficientes de estrogenos en una mujer; composicion farmaceutica que comprende unidades de dosificacion diarias de hemidrato de estradiol > 0,75 y 1
MX352824B (es) Uso de levocetirizina y montelukast en el tratamiento de influenza, resfriado común e inflamación.
MY175764A (en) Extended-release formulation for reducing the frequency of urination and method of use thereof
MX336154B (es) Tratamiento de atrofia vaginal en mujeres con riesgo de patologia tumoral.
MX342417B (es) Composicion antioxidante para reducir el estres oxidativo atribuible al tratamiento con farmacos anticonceptivos hormonales.
PH12013500401A1 (en) Quinoxaline compound
MY172530A (en) Method for treating gynecological diseases
WO2016014680A8 (en) Oral transmucosal compositions including aromatase inhibitors for low testosterone levels in men
WO2010069621A8 (en) Treatment of vaginal atrophy in women with cardiovascular pathology risk
WO2014058853A3 (en) Igm therapy in prevention of onset, progression, and recurrence of autoimmune type 1 diabetes
BRPI0702847A (pt) formas de dosagem unitária de temozolomida

Legal Events

Date Code Title Description
GB Transfer or rights